

General Information

MEETING VENUE

Hilton Milan Hotel
Via L. Galvani,12
20124 Milano - Italy
Ph. +39 02 69831
www.hiltonhotels.it

ITALIAN CME

The application for Italian CME has been made as follows:

- Provider Studio ER Congressi SRL - ID 828-175022
- No. 7 CME credits for physicians (disciplines: hematology and oncology)
- Educational objective:
“guidelines-protocols-procedures”.

SCIENTIFIC SECRETARIAT

Prof. Paolo Corradini

Dipartimento di Ematologia e
Oncoematologia Pediatrica
Fondazione IRCCS Istituto Nazionale dei Tumori
Università degli Studi di Milano
e-mail: paolo.corradini@unimi.it

Prof. Pier Luigi Zinzani

Istituto di Ematologia e Oncologia Medica
“Lorenzo e Ariosto Seràgnoli”
Università degli Studi di Bologna
Via Massarenti, 9 - 40138 Bologna
e-mail: pierluigi.zinzani@unibo.it

ORGANIZING SECRETARIAT

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna - Italy
Ph. +39 051 4210559 - Fax +39 051 4210174
email: ercongressi@ercongressi.it
www.ercongressi.it

Highlights from International Symposium on Hodgkin Lymphoma

Scientific Coordinators:

Paolo Corradini

Pier Luigi Zinzani



MILAN

Unrestricted Educational Grant of



January 19, 2017

HILTON MILAN HOTEL

09.30 – 09.45 Welcome and Introduction
P. Corradini (Milano)
P.L. Zinzani (Bologna)

Session I: Biology and prognostic factors

Chairmen: F. Di Raimondo (Catania)
G. Semenzato (Padova)

09.45 – 10.15 Pathology and pathogenesis
S.A. Pileri (Milano)

10.15 – 10.45 NGS findings
E. Tiacci (Perugia)

10.45 – 11.15 Prognostic factors
L. Rigacci (Firenze)

11.15 – 11.30 Coffee Break

Session II: Clinical updates

Chairmen: A. Santoro (Rozzano - MI)
A. Rambaldi (Bergamo)

11.30 – 12.00 Update in early stages
M. Balzarotti (Milano)

12.00 – 12.30 Update in advanced stages
S. Viviani (Milano)

12.30 – 13.00 Second malignancies and survivorship surveillance
S. Hohaus (Roma)

13.00 – 14.00 Lunch

Session III: Role of new drugs in the current clinical management

Chairmen: M. Martelli (Roma)
G. Rossi (Brescia)

14.00 – 14.30 Explaining the biology underlying the efficacy of Brentuximab Vedotin
A. Pinto (Napoli)

14.30 – 15.00 How to optimize the treatment in the post ASCT setting
A.M. Carella (Genova)

15.00 – 15.30 Treatment of elderly patients
G. Gini (Ancona)

15.30 – 16.00 Role of allogeneic transplant and immunotherapy
P. Corradini (Milano)

Session IV: The management of the future and current clinical trials

Chairman: U. Vitolo (Torino)

16.00 – 16.30 Overview on the future therapeutic landscape of Hodgkin Lymphoma
P.L. Zinzani (Bologna)

16.30 – 17.00 Update on going clinical trials in Hodgkin Lymphoma
C. Rusconi (Milano)

17.00 – 17.30 CME evaluation questionnaire
P. Corradini (Milano),
P.L. Zinzani (Bologna)

17.30 – 18.00 Conclusions and Arrivederci
P. Corradini (Milano),
P.L. Zinzani (Bologna)